Dec 8 (Reuters) - Sirona Biochem Corp SBM.V :
* Sirona Biochem Corp - "expect to receive one or more term sheets from interested parties before end of Q4 2016" for licensing agreement for TFC-1067
* Sirona Biochem Corp - Wanbang Biopharmaceuticals will formulate product (SGLT2 inhibitor) in January 2017 to prepare for a clinical trial
* Sirona Biochem - Wanbang Biopharma will conduct additional pharmacology, toxicology study and file IND package with Chinese FDA for SGLT2 inhibitor
* Sirona Biochem Corp - Valeant is aware of delays in scale-up and has not altered plans to commercialize skin lightener, TFC-849 Source text for Eikon: ID:nCCN4K5tnb Further company coverage: SBM.V